An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

REACT study group, Patricia Soetekouw

Research output: Contribution to journalArticleAcademicpeer-review

71 Citations (Web of Science)
Original languageEnglish
Pages (from-to)324-332
JournalEuropean Journal of Cancer
Volume48
Issue number3
DOIs
Publication statusPublished - Feb 2012

Keywords

  • Advanced kidney cancer
  • mTOR inhibitor
  • RAD001
  • REACT
  • Safety
  • Second-line therapy

Cite this